29 results
424B3
PYXS
Pyxis Oncology Inc
30 Jun 23
Prospectus supplement
4:05pm
. Less frequent related SAEs reported in one patient each have included kidney injury, hepatic failure, bleeding, immune-mediated encephalitis, myositis … of approvals. Regardless of the merits or eventual outcome, liability claims may also result in decreased demand for Apexigen’s products, injury
S-4/A
g56fb8ds
29 Jun 23
Registration of securities issued in business combination transactions (amended)
4:09pm
S-4
etx2fv5 tyjm1t06wp
8 Jun 23
Registration of securities issued in business combination transactions
8:03am
10-K
04zvms3cscjrk6obx
29 Mar 22
Annual report
7:36am
10-Q
tt5rk7c0 7k
15 Nov 21
Quarterly report
7:54am
424B4
a3rfnrg
8 Oct 21
Prospectus supplement with pricing info
5:00pm
S-1/A
EX-10.15
wtenek upa
30 Sep 21
IPO registration (amended)
9:11pm
S-1/A
EX-10.14
3v70hsyyn2dzx6d7mv7
30 Sep 21
IPO registration (amended)
9:11pm
S-1
k0rjv3 2iy
17 Sep 21
IPO registration
5:00pm